scholarly journals Key Factors Influencing Italian Mothers’ Intention to Vaccinate Sons against HPV: The Influence of Trust in Health Authorities, Anticipated Regret and Past Behaviour

2019 ◽  
Vol 11 (23) ◽  
pp. 6879 ◽  
Author(s):  
Caso ◽  
Carfora ◽  
Starace ◽  
Conner
Keyword(s):  
Theory Of Planned Behaviour ◽  
Hpv Vaccination ◽  
Anticipated Regret ◽  
Key Factors ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Integrated Theory ◽  
Health Authorities ◽  
Different Types ◽  
Tpb Model

The Human Papillomavirus (HPV), which is the most common sexually transmitted infection in the world, is associated with different types of cancer, especially cervical cancer. In Italy in 2017 the Italian Ministry of Health introduced a free HPV vaccination programme for 12-years-old boys. In this study we tested an integrated theory of planned behaviour (TPB) model to explain Italian mothers’ intention to vaccinate their sons against HPV. TPB variables plus past behaviour, trust in healthy authorities and anticipated regret were measured by a questionnaire in a sample of 333 Italian mothers of 6–11 years old boys, who were not yet vaccinated against HPV. Results showed that subjective norm was the strongest predictor of mothers’ intention followed by anticipated regret, trust in health authorities, perceived behavioural control and attitude. Mediation analysis found that past behaviour influenced intention via attitude. The discussion considers the relevance of these factors in promoting mothers’ adherence.

Using The Health Belief Model to Explore Female's Perceptions of Male HPV Vaccination

2020 ◽  
Vol 30 (4) ◽  
Author(s):  
Rebecca Vidourek ◽  
Keith King ◽  
Brittany Rosen ◽  
Sara Fehr
Keyword(s):  
Hpv Vaccination ◽  
Health Belief ◽  
Transmitted Infection ◽  
Papilloma Virus ◽  
Sexually Transmitted ◽  
Vaccination Rates ◽  
Midwestern University ◽  
Belief Model ◽  
The Health Belief Model

Background: Human Papilloma Virus (HPV) is a common sexually transmitted infection. The HPV vaccination is an effective method of preventing cervical cancer and genital warts. The present study examined females’ perceptions of male HPV vaccination. Methods: Participants were females (N = 306) from one Midwestern university. Results: Results indicated significant differences in perceived benefits to male HPV vaccination students’ based on grade and knowing a male/female that had the vaccine. No significant differences in perceived barriers were found in the study. Conclusions: These findings should be considered when developing programs aimed at educating students on the male HPV vaccine. The role of females in increasing male HPV vaccination rates should be considered.

Review of Evidence and Recommendation for Human Papillomavirus (HPV) Vaccination of Canadian Males Over the Age of 26 Years

2020 ◽  
Vol 24 (3) ◽  
pp. 285-291 ◽  
Author(s):  
Alex Derstenfeld ◽  
Kyle Cullingham ◽  
Zhuo Cai Ran ◽  
Ivan V. Litvinov
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Older Men ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Vaccination Programs ◽  
Sexually Transmitted ◽  
Control And Prevention

Human papillomavirus (HPV) remains the most common sexually transmitted infection with a lifetime incidence of over 75%. Based on US data from the Centers for Disease Control and Prevention (CDC), 64% of invasive HPV-associated cancers are attributable to HPV 16 or 18 (65% for females; 63% males) and may be prevented by vaccination with either the quadrivalent or nonavalent HPV vaccine. Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada. Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age. There now exist compelling reasons to recommend vaccination against HPV amongst males >26 years of age. Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.

scholarly journals Preparations for implementing human papillomavirus vaccination should begin

2005 ◽  
Vol 10 (37) ◽  
Author(s):  
M Lehtinen
Keyword(s):  
Human Papillomavirus ◽  
World Health Organization ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccination ◽  
World Health ◽  
Human Papillomavirus Vaccination ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
National Programmes ◽  
Health Organization

At a World Health Organization meeting, the latest developments in human papillomavirus (HPV) vaccination were discussed. The leading theme that emerged was how to implement within national programmes the concept of vaccinating adolescents both against a common sexually transmitted infection

scholarly journals Benefits of Gender-Neutral Vaccination Strategy for the Prevention of HPV-Associated Diseases and the Eradication of HPV Infection in General. Current State of HPV Vaccination in the World

2021 ◽  
Vol 18 (3) ◽  
pp. 239-244
Author(s):  
Tatiana E. Privalova ◽  
Olga V. Surovtseva ◽  
Dmitry V. Andriyanov
Keyword(s):  
Hpv Vaccination ◽  
Vaccination Strategy ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Associated Diseases ◽  
Current State ◽  
Papillomavirus Infection ◽  
The World ◽  
Gender Neutral

Papillomavirus infection (HPV infection) is the leading sexually transmitted infection in prevalence. HPV infection and associated diseases, including cancer, remain one of the global problems of our time. This literature review presents relevant data from foreign studies and domestic works on the state of HPV vaccination in the world, the modern vaccines efficacy for the HPV-associated diseases prevention, current vaccination strategies and their efficacy as well. The aim of the article is to determine the advantages of using gender-neutral vaccination strategy over priority-used vaccination strategy for girls only in the prevention of HPV-associated diseases, including cancer, as well as for eradicating HPV infection in general.

Anal and oral human papillomavirus infection in men who have sex with men: implications for risk-targeted vaccination

2020 ◽  
Vol 15 (18) ◽  
pp. 1713-1722
Author(s):  
Maria Gabriella Donà ◽  
Francesca Rollo ◽  
Alessandra Latini ◽  
Maria Benevolo ◽  
Barbara Pichi ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Linear Array ◽  
Hpv Vaccination ◽  
Risk Groups ◽  
Sexually Active ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Papillomavirus Infection ◽  
Significant Burden ◽  
Sex With Men

Aim: Men who have sex with men (MSM) harbor a significant burden of human papillomavirus (HPV)-related diseases that could be prevented by vaccination. Materials & methods: Prevalence of HPVs targeted by the quadrivalent (4vHPV) and nonavalent vaccines (9vHPV) was assessed in anal (n = 443) and oral (n = 193) specimens of immunocompetent, sexually active MSM, using the Linear Array. Results: Of the anal samples, 34.1 and 46.0% were positive for at least one genotype of those covered by the 4vHPV and 9vHPV, respectively. At least one of the HPVs targeted by the 9vHPV was detected in 5.7% of the oral specimens. Conclusion: The majority of the subjects were not currently infected by HPV-16 and other vaccine-preventable HPVs. Universal HPV vaccination should be strongly promoted in order to achieve protection for all risk groups. In the meanwhile, vaccination should be offered to sexually active adult MSM attendees of sexually transmitted infection centers, although its potential benefit for these subjects needs to be further investigated.

Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis

2020 ◽  
Vol 31 (7) ◽  
pp. 606-612
Author(s):  
Husein Husein-ElAhmed
Keyword(s):  
Human Papillomavirus ◽  
Meta Analysis ◽  
Hpv Vaccination ◽  
Genital Warts ◽  
Control Group ◽  
Effect Estimate ◽  
Human Papillomavirus Vaccine ◽  
Eligibility Criteria ◽  
Transmitted Infection ◽  
Sexually Transmitted

Human papillomavirus (HPV) is the most prevalent sexually transmitted infection worldwide and ano-genital warts (AGWs) are highly infectious. This virus is transmitted through sexual, anal, or oral contact as well as skin-to-skin contacts. Treatment for this condition has significant morbidity and it can be frustrating in certain cases. The HPV vaccination has been demonstrated as a promising strategy of secondary prevention in HPV-related diseases such as head and neck cancers, cervical diseases, and recurrent respiratory papillomatosis. Regarding AGWs, it is unclear whether vaccination can provide analogous clinical benefit. The aim of this work is to systematically review the literature regarding HPV vaccination for secondary disease prevention after treatment of AGWs. From October to December 2018, a systematic search for clinical trials was conducted in five databases: PubMed, MEDLINE, EMBASE, Cochrane, and clinicaltrials.gov using a combination of the following descriptors: ‘gardasil’ OR ‘cervarix’ OR ‘nine-valent’ OR ‘9-valent’ OR ‘vaccine’ AND ‘recurrence’ OR ‘relapse’ AND ‘hpv’ OR ‘papillomavirus’ AND ‘warts’ OR ‘condyloma.’ Data were synthetized and entered in the Review Manager software (RevMan 5.3.5) to perform the meta-analysis. The search yielded 824 potentially relevant studies. Two studies fulfilled the eligibility criteria involving 656 participants. The meta-analysis estimated the rate of recurrence of AGWs was similar between the vaccine group and the control group. The overall effect estimate was 1.02 (0.75–1.38). This is the first meta-analysis exploring the effect of HPV vaccine in preventing the relapse of AGWs. These results suggest that HPV vaccination does not provide secondary benefit in patients with previous AGWs. However, these results cannot be generalized due to the scarce number of RCTs currently available in the literature. The outcomes from future randomized controlled trials (RCTs) are warranted to further clarify the precise effect of the vaccine.

scholarly journals HPV-associated cancers

2019 ◽  
Vol 12 (4) ◽  
pp. 352-356
Author(s):  
Christoph Minichsdorfer
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Screening Tests ◽  
Transmitted Infection ◽  
Vaccination Programs ◽  
Sexually Transmitted ◽  
Associated Lesions ◽  
Anal Cancer Screening

SummaryHuman papilloma virus (HPV) is a DNA virus consisting of approximately 8000 base pairs. HPV represents the most common sexually transmitted infection worldwide. Around 200 different genotypes exist. They are distinguished into low- and high-risk genotypes, depending on the risk of such HPV-associated lesions undergoing malignant transformation. The high-risk genotypes include HPV 16 and 18, which are responsible for a variety of human cancers. The most common malignancies that are associated with HPV infection are cervical cancer, oropharyngeal cancer and anal cancer. Screening for HPV precursor lesions in women has led to a drastic reduction in cervical cancer morbidity and mortality in the last 30 years. Unfortunately no such screening tests are available for other HPV-associated malignancies. With the advent of HPV vaccination programs a marked decrease in the prevalence of HPV was reached in vaccinated individuals. However, since these programs were initiated around 2009 the full effect on the incidence of HPV-associated cancers cannot be fully estimated yet.

scholarly journals Time to consider a targeted HPV vaccination programme for male military recruits

2017 ◽  
Vol 164 (4) ◽  
pp. 284-286 ◽  
Author(s):  
William M J Sharp ◽  
T Nadarzynski ◽  
N E Dufty
Keyword(s):  
Vaccination Programme ◽  
Hpv Vaccination ◽  
Herd Immunity ◽  
Human Papillomaviruses ◽  
Military Population ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Related Disease ◽  
Military Recruits ◽  
The Uk

Human papillomaviruses (HPV) are the most common type of sexually transmitted infection in men but also related to high-risk cancers. This article considers the epidemiology of HPV in the male military population, the UK vaccination programme and the current UK Joint Committee on Vaccination and Immunisation recommendations. Military men may not benefit from HPV herd immunity and may have a different risk profile; vaccination may in turn reduce the operational burden of HPV-related disease within this population. Military men may benefit from a targeted vaccination programme, and the paper calls for urgent consideration of approaches that could protect them from acquiring HPV.

scholarly journals Epidemiology of genital warts in the British population: implications for HPV vaccination programmes

2019 ◽  
Vol 95 (5) ◽  
pp. 386-390 ◽  
Author(s):  
Pam Sonnenberg ◽  
Clare Tanton ◽  
David Mesher ◽  
Eleanor King ◽  
Simon Beddows ◽  
...  
Keyword(s):  
Hpv Vaccination ◽  
Genital Warts ◽  
Sample Survey ◽  
Similar Proportion ◽  
Computer Assisted ◽  
Transmitted Infection ◽  
Men And Women ◽  
Sexually Transmitted ◽  
Sex With Men ◽  
Sexual Health Clinics

ObjectivesTo estimate the prevalence of, and describe risk factors for, genital warts (GWs) in the British population, following the introduction of the bivalent (human papillomavirus (HPV)-16/18) vaccination programme in girls, and prior to the switch to quadrivalent (HPV-6/11/16/18) vaccine (offering direct protection against GWs) and compare this with GW diagnoses in the prevaccination era.MethodsNatsal-3, a probability sample survey in Britain, conducted in 2010–2012, interviewed 9902 men and women aged 16–44. Natsal-2, conducted in 1999–2001, surveyed 11 161 men and women aged 16–44. Both surveys collected data on sexual behaviour and sexually transmitted infection diagnoses using computer-assisted interview methods.ResultsIn Natsal-3, 3.8% and 4.6% of sexually experienced men and women reported ever having a diagnosis of GWs, with 1.3% of men and 1.7% of woman reporting a GWs diagnosis in the past 5 years. GWs were strongly associated with increasing partner numbers and condomless sex. Diagnoses were more frequent in men who have sex with men (MSM) (11.6% ever, 3.3% past 5 years) and in women reporting sex with women (10.8% ever, 3.6% past 5 years). In the age group who were eligible for vaccination at the time of Natsal-3 (16–20 years), a similar proportion of same-aged women reported a history of GWs in Natsal-2 (1.9%, 1.1–3.4) and Natsal-3 (2.6%, 1.5–4.4).ConclusionsThese data provide essential parameters for mathematical models that inform cost-effectiveness analyses of HPV vaccination programmes. There was no evidence of population protection against GWs conferred by the bivalent vaccine. Even with vaccination of adolescent boys, vaccination should be offered to MSM attending sexual health clinics.

Sign in / Sign up

Export Citation Format

Share Document